| answer text |
<p>Since 2019, patients in the National Health Service have been able to access Orkambi,
Symkevi and Kaftrio through an interim access agreement between NHS England, the company
(Vertex), the National Institute for Health and Care Excellence (NICE) and the UK
Cystic Fibrosis Trust.</p><p> </p><p>The agreement makes the medicines available for
a limited time at a reduced price, while further information has been collected to
inform a NICE appraisal. On 15 November 2023, the Medicines and Healthcare products
Regulatory Agency (MHRA) approved a new licence extension and children as young as
two years old with cystic fibrosis are now eligible to receive Kaftrio through the
interim access agreement.</p><p> </p><p>NICE is currently consulting on its draft
recommendations on the use of Orkambi, Symkevi and Kaftrio and has not yet published
its final recommendations. NICE continues to work with stakeholders to address the
issues highlighted by the committee in the draft guidance. Under the terms of the
interim access agreement for the cystic fibrosis medicines, Orkambi, Symkevi and Kaftrio,
eligible children and adults with cystic fibrosis can continue to receive ongoing
treatment and be initiated onto treatment with these medicines, as clinically appropriate,
while NICE concludes its evaluation.</p>
|
|
